Cargando…
Biosensors for inflammation as a strategy to engineer regulatory T cells for cell therapy
Engineered regulatory T cell (Treg cell) therapy is a promising strategy to treat patients suffering from inflammatory diseases, autoimmunity, and transplant rejection. However, in many cases, disease-related antigens that can be targeted by Treg cells are not available. In this study, we introduce...
Autores principales: | Bittner, Sebastian, Ruhland, Brigitte, Hofmann, Veronika, Schmidleithner, Lisa, Schambeck, Kathrin, Pant, Asmita, Stüve, Philipp, Delacher, Michael, Echtenacher, Bernd, Edinger, Matthias, Hoffmann, Petra, Rehli, Michael, Gebhard, Claudia, Strieder, Nicholas, Hehlgans, Thomas, Feuerer, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546553/ https://www.ncbi.nlm.nih.gov/pubmed/36161919 http://dx.doi.org/10.1073/pnas.2208436119 |
Ejemplares similares
-
Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells
por: Delacher, Michael, et al.
Publicado: (2021) -
Precursors for Nonlymphoid-Tissue Treg Cells Reside in Secondary Lymphoid Organs and Are Programmed by the Transcription Factor BATF
por: Delacher, Michael, et al.
Publicado: (2020) -
Quantitative Proteomics Identifies TCF1 as a Negative Regulator of Foxp3 Expression in Conventional T Cells
por: Delacher, Michael, et al.
Publicado: (2020) -
Rbpj expression in regulatory T cells is critical for restraining T(H)2 responses
por: Delacher, Michael, et al.
Publicado: (2019) -
Premature Expression of Foxp3 in Double-Negative Thymocytes
por: Barra, Melanie M., et al.
Publicado: (2015)